SXTP VS AVGR Stock Comparison

PerformanceProfitVolatilityAnalyst Price TargetsTechnicalsEarnings
PerformanceProfitVolatilityAnalyst Price TargetsTechnicalsEarnings

Performance

SXTP
10/100

SXTP returned -82.63% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AVGR
10/100

AVGR returned -79.08% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Profit

SXTP
10/100

Out of the last 4 quarters, SXTP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

AVGR
10/100

Out of the last 20 quarters, AVGR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SXTP
38/100

SXTP has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

AVGR
27/100

AVGR has had a lower than average amount of volatility over the last 12 months giving it a score of 27 of 100.

Analyst Price Targets

SXTP

"Analyst Price Targets" not found for SXTP

AVGR
75/100

1 analysts offer 12-month price targets for AVGR. Together, they have an average target of 0, the most optimistic target put AVGR at 0 within 12-months and the most pessimistic has AVGR at 0.

Technicals

SXTP

"Technicals" not found for SXTP

AVGR
18/100

AVGR receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

SXTP

"Earnings" not found for SXTP

AVGR
10/100

AVGR has missed earnings 11 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

60 Degrees Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / SXTP
Healthcare
Biotechnology
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Avinger, Inc. Common Stock Summary

Nasdaq / AVGR
Healthcare
Medical - Instruments & Supplies
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.